Abstract:OBJECTIVE:It is well established that regional cerebral metabolic rates for glucose assessed by [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with Alzheimer's disease in the mental resting state (eyes and ears covered) provide a sensitive, in vivo metabolic index of Alzheimer's disease dementia. Few studies, however, have evaluated longitudinal declines in regional cerebral glucose metabolism in patients with dementia caused by Alzheimer's disease. In addition, the available studies have not used recently developed brain mapping algorithms to characterize the progression of Alzheimer's disease throughout the brain, and none considered the statistical power of regional cerebral glucose metabolism in testing the ability of treatments to attenuate the progression of dementia.METHOD:The authors used FDG PET and a brain mapping algorithm to investigate cross-sectional reductions in regional cerebral glucose metabolism, longitudinal decline in regional cerebral glucose metabolism after a 1-year follow-up, and the power of this method to evaluate treatments for Alzheimer's disease in patients with mild to moderate dementia. PET scans were initially acquired in 14 patients with Alzheimer's disease and 34 healthy comparison subjects of similar age and sex. Repeat scans were obtained in the patients 1 year later. Power analyses for voxels showing maximal decline over the 1-year period in regional cerebral glucose metabolism (mg/100 g per minute) were computed to estimate the sample sizes needed to detect a significant treatment response in a 1-year, double-blind, placebo-controlled treatment study.RESULTS:The patients with Alzheimer's disease had significantly lower glucose metabolism than healthy comparison subjects in parietal, temporal, occipital, frontal, and posterior cingulate cortices. One year later, the patients with Alzheimer's disease had significant declines in glucose metabolism in parietal, temporal, frontal, and posterior cingulate cortices. Using maximal glucose metabolism reductions in the left frontal cortex, we estimated that as few as 36 patients per group would be needed to detect a 33% treatment response with one-tailed significance of p</=0.005 and 80% power in a 1-year, double-blind, placebo-controlled treatment study.CONCLUSIONS:These findings indicate that brain metabolism as assessed by FDG PET during mental rest is a sensitive marker of disease progression in Alzheimer's disease over a 1-year period. These findings also support the feasibility of using FDG PET as an outcome measure to test the ability of treatments to attenuate the progression of Alzheimer's disease.

Twelve-month Metabolic Declines in Probable Alzheimer's Disease and Amnestic Mild Cognitive Impairment Assessed Using an Empirically Pre-Defined Statistical Region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative

O1-04-05: Six-month Cerebral Metabolic Declines in Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Elderly Normal Control Groups: Preliminary Findings from the Alzheimer's Disease Neuroimaging Initiative

O1-02-06: Twelve-month Cerebral Metabolic Declines in Probable Alzheimer's Disease and Amnestic Mild Cognitive Impairment: Preliminary Findings from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

IC‐P1‐036: Categorical and Correlational Analyses of Baseline Fluorodeoxyglucose Positron Emission Tomography Images from the Alzheimer's Disease Neuroimaging Initiative

Categorical and Correlational Analyses of Baseline Fluorodeoxyglucose Positron Emission Tomography Images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer’s Disease Treatment Studies

P-024: the Pattern and Severity of FDG Pet Abnormalities in Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: Preliminary Findings from the Alzheimer’s Disease Neuroimaging Initiative

IC-P2-128: Twelve-month Cerebral Metabolic Declines in Probable Alzheimer's Disease and Amnestic Mild Cognitive Impairment: Preliminary Findings from the Alzheimer's Disease Neuroimaging Initiative

IC-P2-086: the Pattern of Cerebral Hypometablism in Amnestic Mild Cognitive Impairment and Its Relationship to Subsequent Conversion to Probable Alzheimer's Disease: Preliminary Findings from the Alzheimer's Disease Neuroimaging Initiative

P4‐053: Relationship Between Longitudinal, Structural Magnetic Resonance Imaging and [18f]fluorodeoxyglucose Positron Emission Tomography Data from the Alzheimer'S Disease Neuroimaging Initiative Study

P1-338: the Consistency of Hypometabolic Brain Voxels in Probable Alzheimer's Disease and Amnestic Mild Cognitive Impairment Patients from the Alzheimer's Disease Neuroimaging Initiative

Relationship Between Longitudinal, Structural Magnetic Resonance Imaging and [18f]fluorodeoxyglucose Positron Emission Tomography Data From The Alzheimer'S Disease Neuroimaging Initiative Study

Topographic extent of cerebral hypometabolism predicts time of conversion from aMCI to Alzheimer's disease: Data from the Alzheimer's Disease Neuroimaging Initiative

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI

Assessing the Reliability to Detect Cerebral Hypometabolism in Probable Alzheimer's Disease and Amnestic Mild Cognitive Impairment.

P1‐312: Differentiating Amnestic Mild Cognitive Impairment Converting to Probable Alzheimer's Disease from Stable Amnestic Mild Cognitive Impairment Using FDG‐PET and an Alzheimer's Disease‐related Hypometabolism Overlap Index

Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease

Use of an FDG-PET Derived Hypometabolic Convergence Index Enrichment Strategy to Reduce Sample Sizes in Alzheimer's Disease Clinical Trials: Findings from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

DT‐01–06: Baseline FDG‐PET and Volumetric MRI Predicts Alzheimer's Disease Conversion from Mild Cognitive Impairment: an ADNI Study

IC‐P2‐074: Differentiating Amnestic MCI Converting to Probable AD from Stable Amnestic MCI Using FDG‐PET and an AD‐related Hypometabolism Overlap Index

Evaluating the association between brain atrophy, hypometabolism, and cognitive decline in Alzheimer’s disease: a PET/MRI study